(Q80059477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

1 reference

8

Frank M Torti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Lester S Borden

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Peter E Clark

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

James Lovato

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

M Craig Hall

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Diana Stindt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Michele Harmon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Randi M Mohler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

1093-1100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

Carcinoma of the prostate

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Prostate cancer: screening, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Cortisone treatment in advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22078

7 January 2021

Identifiers

DOI

10.1002/CNCR.22078

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16888761%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference